RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

Thoralf Wendt, Evis Harja, Loredana Bucciarelli, Wu Qu, Yan Lu, Ling Ling Rong, Daniel G. Jenkins, Guenther Stein, Ann Marie Schmidt, Shi Fang Yan

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Previous studies demonstrated that induction of diabetes with streptozotocin (stz) accelerated atherosclerosis in hyperlipidemic apo E null (-/-) mice. Blockade of the Receptor for Advanced Glycation Endproducts (RAGE) in those animals suppressed acceleration of atherosclerotic lesion area, in a manner independent of changes in levels of glucose, insulin or lipids. In the present studies, we extended these concepts to a murine model of type 2 diabetes, and bred apo E -/- mice into the db/db background. Db/db mice are a model of obesity and insulin resistance-mediated hyperglycemia. Compared to apo E -/- m/db (non-diabetic) mice, apo E -/- db/db (diabetic) mice displayed accelerated atherosclerosis at the aortic sinus. Consistent with an important role for RAGE in this process, administration of soluble (s) RAGE, the extracellular ligand-binding domain of RAGE, resulted in significantly reduced atherosclerotic lesion area in a glycemia- and lipid-independent manner. In parallel, apo E -/- db/db mice displayed RAGE-dependent enhanced expression of Vascular Cell Adhesion Molecule-1, tissue factor and matrix metalloproteinase (MMP)-9 antigen/activity in aortae compared to non-diabetic animals. In addition, consistent with the premise that upregulation of RAGE ligands and RAGE occurs even in the non-diabetic, hyperlipidemic state, albeit to lesser degrees than in diabetes, administration of sRAGE to apo E -/- m/db mice resulted in decreased atherosclerotic lesion area at the aortic sinus. Taken together, these findings establish a new murine model for the study of atherosclerosis in type 2 diabetes and highlight important roles for RAGE in proatherogenic mechanisms in hyperglycemia triggered by insulin resistance.

Original languageEnglish
Pages (from-to)70-77
Number of pages8
JournalAtherosclerosis
Volume185
Issue number1
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Type 2 Diabetes Mellitus
Blood Vessels
Atherosclerosis
Apolipoproteins E
Inflammation
Sinus of Valsalva
Hyperglycemia
Insulin Resistance
Ligands
Lipids
Experimental Diabetes Mellitus
Vascular Cell Adhesion Molecule-1
Advanced Glycosylation End Product-Specific Receptor
Matrix Metalloproteinase 9
Thromboplastin
Aorta
Up-Regulation
Obesity
Insulin
Antigens

Keywords

  • Atherosclerosis
  • Hyperglycemia
  • RAGE
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. / Wendt, Thoralf; Harja, Evis; Bucciarelli, Loredana; Qu, Wu; Lu, Yan; Rong, Ling Ling; Jenkins, Daniel G.; Stein, Guenther; Schmidt, Ann Marie; Yan, Shi Fang.

In: Atherosclerosis, Vol. 185, No. 1, 03.2006, p. 70-77.

Research output: Contribution to journalArticle

Wendt, T, Harja, E, Bucciarelli, L, Qu, W, Lu, Y, Rong, LL, Jenkins, DG, Stein, G, Schmidt, AM & Yan, SF 2006, 'RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes', Atherosclerosis, vol. 185, no. 1, pp. 70-77. https://doi.org/10.1016/j.atherosclerosis.2005.06.013
Wendt, Thoralf ; Harja, Evis ; Bucciarelli, Loredana ; Qu, Wu ; Lu, Yan ; Rong, Ling Ling ; Jenkins, Daniel G. ; Stein, Guenther ; Schmidt, Ann Marie ; Yan, Shi Fang. / RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. In: Atherosclerosis. 2006 ; Vol. 185, No. 1. pp. 70-77.
@article{59a6840dfd8844b2ab199500a2f10a43,
title = "RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes",
abstract = "Previous studies demonstrated that induction of diabetes with streptozotocin (stz) accelerated atherosclerosis in hyperlipidemic apo E null (-/-) mice. Blockade of the Receptor for Advanced Glycation Endproducts (RAGE) in those animals suppressed acceleration of atherosclerotic lesion area, in a manner independent of changes in levels of glucose, insulin or lipids. In the present studies, we extended these concepts to a murine model of type 2 diabetes, and bred apo E -/- mice into the db/db background. Db/db mice are a model of obesity and insulin resistance-mediated hyperglycemia. Compared to apo E -/- m/db (non-diabetic) mice, apo E -/- db/db (diabetic) mice displayed accelerated atherosclerosis at the aortic sinus. Consistent with an important role for RAGE in this process, administration of soluble (s) RAGE, the extracellular ligand-binding domain of RAGE, resulted in significantly reduced atherosclerotic lesion area in a glycemia- and lipid-independent manner. In parallel, apo E -/- db/db mice displayed RAGE-dependent enhanced expression of Vascular Cell Adhesion Molecule-1, tissue factor and matrix metalloproteinase (MMP)-9 antigen/activity in aortae compared to non-diabetic animals. In addition, consistent with the premise that upregulation of RAGE ligands and RAGE occurs even in the non-diabetic, hyperlipidemic state, albeit to lesser degrees than in diabetes, administration of sRAGE to apo E -/- m/db mice resulted in decreased atherosclerotic lesion area at the aortic sinus. Taken together, these findings establish a new murine model for the study of atherosclerosis in type 2 diabetes and highlight important roles for RAGE in proatherogenic mechanisms in hyperglycemia triggered by insulin resistance.",
keywords = "Atherosclerosis, Hyperglycemia, RAGE, Type 2 diabetes",
author = "Thoralf Wendt and Evis Harja and Loredana Bucciarelli and Wu Qu and Yan Lu and Rong, {Ling Ling} and Jenkins, {Daniel G.} and Guenther Stein and Schmidt, {Ann Marie} and Yan, {Shi Fang}",
year = "2006",
month = "3",
doi = "10.1016/j.atherosclerosis.2005.06.013",
language = "English",
volume = "185",
pages = "70--77",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

AU - Wendt, Thoralf

AU - Harja, Evis

AU - Bucciarelli, Loredana

AU - Qu, Wu

AU - Lu, Yan

AU - Rong, Ling Ling

AU - Jenkins, Daniel G.

AU - Stein, Guenther

AU - Schmidt, Ann Marie

AU - Yan, Shi Fang

PY - 2006/3

Y1 - 2006/3

N2 - Previous studies demonstrated that induction of diabetes with streptozotocin (stz) accelerated atherosclerosis in hyperlipidemic apo E null (-/-) mice. Blockade of the Receptor for Advanced Glycation Endproducts (RAGE) in those animals suppressed acceleration of atherosclerotic lesion area, in a manner independent of changes in levels of glucose, insulin or lipids. In the present studies, we extended these concepts to a murine model of type 2 diabetes, and bred apo E -/- mice into the db/db background. Db/db mice are a model of obesity and insulin resistance-mediated hyperglycemia. Compared to apo E -/- m/db (non-diabetic) mice, apo E -/- db/db (diabetic) mice displayed accelerated atherosclerosis at the aortic sinus. Consistent with an important role for RAGE in this process, administration of soluble (s) RAGE, the extracellular ligand-binding domain of RAGE, resulted in significantly reduced atherosclerotic lesion area in a glycemia- and lipid-independent manner. In parallel, apo E -/- db/db mice displayed RAGE-dependent enhanced expression of Vascular Cell Adhesion Molecule-1, tissue factor and matrix metalloproteinase (MMP)-9 antigen/activity in aortae compared to non-diabetic animals. In addition, consistent with the premise that upregulation of RAGE ligands and RAGE occurs even in the non-diabetic, hyperlipidemic state, albeit to lesser degrees than in diabetes, administration of sRAGE to apo E -/- m/db mice resulted in decreased atherosclerotic lesion area at the aortic sinus. Taken together, these findings establish a new murine model for the study of atherosclerosis in type 2 diabetes and highlight important roles for RAGE in proatherogenic mechanisms in hyperglycemia triggered by insulin resistance.

AB - Previous studies demonstrated that induction of diabetes with streptozotocin (stz) accelerated atherosclerosis in hyperlipidemic apo E null (-/-) mice. Blockade of the Receptor for Advanced Glycation Endproducts (RAGE) in those animals suppressed acceleration of atherosclerotic lesion area, in a manner independent of changes in levels of glucose, insulin or lipids. In the present studies, we extended these concepts to a murine model of type 2 diabetes, and bred apo E -/- mice into the db/db background. Db/db mice are a model of obesity and insulin resistance-mediated hyperglycemia. Compared to apo E -/- m/db (non-diabetic) mice, apo E -/- db/db (diabetic) mice displayed accelerated atherosclerosis at the aortic sinus. Consistent with an important role for RAGE in this process, administration of soluble (s) RAGE, the extracellular ligand-binding domain of RAGE, resulted in significantly reduced atherosclerotic lesion area in a glycemia- and lipid-independent manner. In parallel, apo E -/- db/db mice displayed RAGE-dependent enhanced expression of Vascular Cell Adhesion Molecule-1, tissue factor and matrix metalloproteinase (MMP)-9 antigen/activity in aortae compared to non-diabetic animals. In addition, consistent with the premise that upregulation of RAGE ligands and RAGE occurs even in the non-diabetic, hyperlipidemic state, albeit to lesser degrees than in diabetes, administration of sRAGE to apo E -/- m/db mice resulted in decreased atherosclerotic lesion area at the aortic sinus. Taken together, these findings establish a new murine model for the study of atherosclerosis in type 2 diabetes and highlight important roles for RAGE in proatherogenic mechanisms in hyperglycemia triggered by insulin resistance.

KW - Atherosclerosis

KW - Hyperglycemia

KW - RAGE

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=30944454884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944454884&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2005.06.013

DO - 10.1016/j.atherosclerosis.2005.06.013

M3 - Article

C2 - 16076470

AN - SCOPUS:30944454884

VL - 185

SP - 70

EP - 77

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -